ERBB2 and neoplasm: HER2-targeted therapies, such as trastuzumab and pertuzumab, can enhance the immune recognition of HER2-positive tumor cells by promoting antibody-dependent cellular cytotoxicity (ADCC) and immune-mediated tumor cell death [84].